Antibiotics Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMPH913 | Last Updated On: Jun 24 2022 | Available Formats

> Global Antibiotics Market Expected to reach a high CAGR of 5% By 2029: DataM Intelligence

Global Antibiotics Market is segmented by Drug Class (Penicillin ,Cephalosporin,Fluoroquinolones,Carbapenem, Macrolides, Sulfonamides, Aminoglycosides and others) , By Spectrum (Narrow-spectrum Antibiotics, Broad-spectrum Antibiotics), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

Market Overview

Global "Antibiotics Market" is Expected to reach at a high CAGR of 5% during the forecasting period (2022-2029).

Antibiotics are medications that destroy or slow down the growth of bacteria. They are also known as antibacterial and include a range of powerful drugs and are used to treat diseases caused by bacteria. These are among the most prescribed courses worldwide in fighting bacterial infections, primarily in outpatient settings.

Market Dynamics

The global antibiotics market growth is driven by the increased consumption of antibiotics in low & middle-income countries, major investments in R&D activities by pharmaceutical companies, and a rise in the prevalence of infectious diseases.

The rising prevalence of bacterial infections will drive the market growth    

The rising prevalence of bacterial infections and the need for effective and newer antibiotics are driving the demand for advanced antibiotics. For instance, according to the October 2021 report of the World Health Organization (WHO), about 1.5 million people worldwide died because of tuberculosis (TB) in 2020, and approximately 10 million people fell ill with TB globally. As per the same source from WHO, of the estimated new cases of tuberculosis in 2020, 1.1 million were in children, and 86% of the TB cases were reported from the 30 high TB burden countries. One-third of the total cases were reported from eight countries, including India, China, Indonesia, Philippines, Pakistan, Nigeria, Bangladesh, and South Africa.

With the urbanization and destruction of natural habitats, climate change, and changing ecosystems, the rate of emergence of infectious diseases has increased recently. The population group primarily affected by these infectious diseases in people aged 65 and more (geriatric population). They are more prone to contracting infection due to their less responsive immune system. Thus, the growing geriatric population around the world is further expected to increase the demand for antibiotics worldwide and augment the growth in the antibiotics market over the forecast period. For instance, as per the World Population Ageing Highlight 2020 report published by the United Nations, the global geriatric population is expected to increase from 727 million in 2020 to 1.5 billion by 2050, which is an almost two-fold increase as the share of the geriatric population in 2020 was about 9.3%, which is projected to increase to 16% by 2050. Thus, with the growing aging population, the burden of infectious diseases is expected to increase, complementing the growth of the market during the forecast period.

The growing prevalence of antibiotics resistance will hamper the growth of the market

However, factors such as the growing prevalence of antibiotics resistance, regulatory constraints, and decreasing number of companies involved in the research of antibiotics are expected to impede the growth of the antibiotics market over the forecast period.   

COVID-19 Impact Analysis

COVID-19 impacted the global supply chain of pharmaceuticals, affecting the antibiotics market. However, many antibiotics were initially used to treat COVID-19 and are widely prescribed and studied as the COVID-19 remedy. For instance, in March 2020, Pfizer announced positive data for using its azithromycin (Zithromax) drug, along with hydroxychloroquine, in a coronavirus (COVID-19) clinical trial performed in France. There was a huge demand for antibiotics during the COVID-19 pandemic, which also impacted the studied market of antibiotics. For instance, according to a July 2021 published article titled, “Sales of antibiotics and hydroxychloroquine in India during the COVID-19 epidemic, An interrupted time series analysis”, COVID-19 contributed to about 216 million excess doses of non-CAF (child-appropriate formulations) of antibiotics in total and 38 million excess doses of azithromycin between June and September 2020 in India.

Segment Analysis

The cephalosporins segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)        

Cephalosporins are a type of beta-lactam antibiotic that helps inhibit the synthesis of peptidoglycan, which are present in the bacterial cell wall and thus, used to manage a wide range of infections from gram-positive and gram-negative bacteria. These antibiotics are commonly used to treat pneumonia, skin infections, ear infections, meningitis, upper respiratory tract infections, etc.

Each advancement was termed as a generation, and currently, there are five generations of cephalosporins. Due to their wide applicability and flexible route of administration (oral or intravenous), cephalosporins are prescribed and used widely around the world, which is the major factor for their growth in the antibiotics market. Also, with the growing incidences of infection, the companies are evolving their product offering and launching new ones, which is expected to significantly impact the growth of the studied market over the years. For instance, in November 2019, the United States Food and Drug Administration (FDA) approved Cefiderocol (Fetroja) for the treatment of complicated urinary tract infections (UTI), including pyelonephritis caused by susceptible gram-negative bacteria.

Geographical Analysis

North America region holds the largest market share of the global antibiotics market

North America dominates the market for antibiotics and is expected to show a similar trend over the forecast period, owing to the high demand and consumption of antibiotics in the region due to the high burden of infectious diseases and the growing aging population.

For instance, according to the October 2021 update of the Centers for Disease Control and Prevention (CDC), in 2020, approximately 7,174 new cases of tuberculosis (TB) were reported in the United States. As per the same source, the prevalence of TB was reported to be highest among Hispanic or Latino persons, who accounted for about 30% of the total TB cases reported in the country. Thus, the presence of new TB cases in the country is expected to drive the demand for antibiotics in the region which is likely to drive the growth of the studied market in the region.

The other major factor that will complement the demand for antibiotics in the region is the growing geriatric population, more prone to infections. For instance, according to the World Population Ageing Highlight report of 2019 published by the United Nations, the geriatric (aged 65 years and more) population of the United States was 53, 340, 00; 6,602,000 in Canada, and 9,462,000 in Mexico. By 2050, it is projected to increase to 26,416,000 in Mexico, 11,436,000 in Canada, and 84,813,000 in the United States.

Competitive Landscape

The antibiotics market is a moderately competitive presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include GlaxoSmithKline PLC, Johnson & Johnson Inc., Merck & Co. Inc., Pfizer Inc., Bayer Healthcare AG, Novartis AG, Sanofi SA, Abbott Laboratories, F. Hoffmann-La Roche AG, and Otsuka Pharmaceutical Co. Ltd among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the antibiotics market globally. For instance, in October 2021, Otsuka received approval for an additional pediatric indication in Europe. Otsuka has been working on expanding access to DELTYBA worldwide in support of that effort.

Bayer AG

Overview:

Bayer AG produces and markets healthcare and agricultural products. The Company manufactures products that include aspirin, antibiotics, anti-Infectives, cardiovascular, oncology, central nervous system drugs, over-the-counter medications, diagnostics, and animal health products, as well as crop protection products, plastics, and polyurethanes.     

Product Portfolio:

Adempas (riociguat):  Adempas (riociguat) is a soluble guanylate cyclase (sGC) stimulator, the first member of a distinct class of compounds, discovered and developed by Bayer as an oral treatment to target a key molecular mechanism underlying pulmonary hypertension.

Trending Topics

Veterinary Antibiotics Market

Transthyretin Amyloid Cardiomyopathy Market

Lichen Sclerosus Treatment Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest